Joseph G. Pressey · Challenges in the Treatment of Sarcomas of Adolescents and Young Adults
Follow
Article1 min read·Published Jun 2017Older

Challenges in the Treatment of Sarcomas of Adolescents and Young Adults

pubmed.ncbi.nlm.nih.gov shows its articles on its own site.

Read the article on pubmed.ncbi.nlm.nih.gov ↗

Article · Jun 2017 · 1 min read

In brief

In brief

Adolescent and young adult sarcoma patients experience worse outcomes than younger patients due to distinct tumor biology, higher treatment toxicity, and psychosocial barriers including financial strain and treatment adherence challenges. Low clinical trial participation limits development of age-appropriate protocols and biospecimen collection for research.

Written by the GCMD Library team from the article.

Joseph G. Pressey

Adolescent and young adult (AYA) sarcoma patients do not fare as well as their younger counterparts. A variety of factors theorized to underlie such disparate outcomes have been identified including distinct tumor and host biology. Compared to younger patients, AYA patients often develop genetically distinct tumors and are more likely to suffer characteristic therapy-related toxicities. Compounding factors faced by AYA patients include education, finances, employment, and obstacles to treatment adherence. Lack of clinical trial participation among AYA patients has slowed the establishment of optimized age-specific treatment protocols and hindered the collection of biospecimens for scientific investigation. The relative rarity of sarcomas among adult cancers may limit the familiarity of oncologists with state of the art diagnostic and therapeutic aspects of sarcomas in young adults. Among other interventions, improved enrollment on clinical trials is a critical step in addressing the challenges faced by AYA patients. Further insight into unique tumor and host biology among AYA patients is also an important need.

Statements in this article

  1. Adolescent and young adult sarcoma patients do not fare as well as their younger counterparts.

    Established
  2. Compared to younger patients, AYA patients often develop genetically distinct tumors.

    Established
  3. AYA patients are more likely to suffer characteristic therapy-related toxicities compared to younger patients.

    Established
  4. Lack of clinical trial participation among AYA patients has slowed the establishment of optimized age-specific treatment protocols.

    Established
  5. The relative rarity of sarcomas among adult cancers may limit the familiarity of oncologists with state of the art diagnostic and therapeutic aspects of sarcomas in young adults.

    Established
  6. Improved enrollment on clinical trials is a critical step in addressing the challenges faced by AYA patients.

    Recommendation

Read it at the source ↗

Try
Intelligent Search· scoped to this article · not medical adviceSearch the whole library →
GCMD Library — educational content from recorded physician discussions, not medical advice.